Xencor opened lower at $29.09, compared with its previous close of $29.21. In the last trading session, the stock traded between $28.61 and $29.58. It showed a sideways intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Xencor is now worth
$ 73.79
resulting in a loss of
$ 26.21 (26.21%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 13 Analysts
Buy
84.62%
Hold
15.38%
Sell
0%
Markets Today
Today's Change
$-0.02 (-0.07%)
Day High
$29.58
Day Low
$28.61
Day Open
$29.09
Prev Close
$29.21
Volume
3,64,370
1W Return
12.88%
1M Return
16.69%
3M Return
49.36%
6M Return
151.20%
1Y Return
98.98%
Fundamentals
Market Cap ($ Mn)
2,170
PE Ratio
-
PB Ratio
3.84
PEG Ratio
-
ROE
-14.40%
ROCE
-10.58%
EPS (TTM)
$-0.29
Investment Returns
1 Week
12.88%
1 Month
16.69%
3 Months
49.36%
6 Months
151.20%
9 Months
135.78%
Financials
Quarterly
All values in $ Mn
70.0
Dec 24
32.7
Mar 25
43.6
Jun 25
21.0
Sep 25
28.2
Dec 25
51.2
Jun 26
Updates
6Aug
Cantor Fitzgerald raises Xencor price target to $44, keeps Overweight rating
Cantor Fitzgerald analyst Steve Seedhouse raised Xencor's price target to $44 from $43. The firm maintains its Overweight rating on the NASDAQ-listed biotechnology company, signaling continued confidence in its investment potential.
2mo ago
6Aug
Xencor Q2 EPS beats estimate as sales surge 170 percent
Xencor delivered stronger-than-expected Q2 results with EPS of $(0.29) versus a $(0.79) estimate. Sales of $51.200 million exceeded forecasts by 170.59 percent and grew 17.41 percent year-over-year. However, per-share losses widened 29.27 percent compared to the prior year period.
2mo ago
30Jul
Wedbush reiterates outperform on Xencor, keeps $26 price target
Wedbush analyst David Nierengarten reiterates an Outperform rating on Xencor with an unchanged $26 price target. The move reflects steady confidence in the biotech firm's prospects without requiring valuation adjustments based on recent market activity.
3mo ago
30Jul
Xencor secures $105M from Alexion to settle Ultomiris U.S. royalties
Xencor resolves a royalty dispute with Alexion for $105 million, payable in two $52.5 million installments starting August 2026. The deal ends U.S. royalty obligations but preserves ex-U.S. rights, extending Xencor's cash runway through 2028.
3mo ago
17Jul
Xencor to present Phase 1 XmAb819 data at ESMO 2026
Xencor announced that Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma were accepted for a proffered paper oral presentation at the ESMO Congress 2026 in Madrid. The presentation will highlight expansion-cohort results, and a pivotal Phase 3 study is planned for 2027.
